Catalyst Pharmaceuticals (CPRX) Cash & Equivalents (2010 - 2026)

Catalyst Pharmaceuticals has reported Cash & Equivalents for 17 years, with the latest figure at $755.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 30.17% year-over-year to $755.9 million; the trailing twelve-month figure through Mar 2026 stood at $755.9 million (up 30.17% YoY), and the FY2025 full-year result was $709.2 million, up 37.02% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $755.9 million, up from $709.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $755.9 million in Q1 2026, with the low at $121.0 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $386.1 million across 5 years, with a median of $310.4 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 53.87% — and 2024, when it jumped 276.03%.
• Catalyst Pharmaceuticals' Cash & Equivalents stood at $298.4 million in 2022, then slumped by 53.87% to $137.6 million in 2023, then jumped by 276.03% to $517.6 million in 2024, then surged by 37.02% to $709.2 million in 2025, then increased by 6.58% to $755.9 million in 2026.
• The last three Cash & Equivalents figures came in at $755.9 million (Q1 2026), $709.2 million (Q4 2025), and $689.9 million (Q3 2025), per Business Quant data.